Welcome to Lyndra Therapeutics: Medicine, reinvented
 
Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible.
 
Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication.
 
Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.
 
Core purpose: reinvent medicine for a healthier world
 
Core values: value every voice; resilient to the core; I contribute, we deliver
 
Does Lyndra sound like a great fit for you? Join the Team: https://lyndra.com/about/join-the-team/

AIG Investments

Polaris Partners

Quark Venture

Limitless Ventures

Mass General Brigham Ventures

THE CATALYTIC IMPACT FOUNDATION (CIF)

Yipinhong Pharmacy

Gilead Sciences

HOPU Investment Management Company

ImpactAssets

Sarissa Capital Management

Sun Pharmaceutical Industries

Lyndra Therapeutics

At Lyndra, our team is eager to bring long-acting oral therapies to people who need them. Today, we announced positive data from our pivotal phase 3 study of oral weekly risperidone (LYN-005) for schizophrenia. As our Chief Medical Officer and President of Global Product Development, Richard Scranton MD MPH shared, “These positive data demonstrate that a single dose of oral weekly risperidone delivers comparable medication levels to daily risperidone, validating that Lyndra’s LYNX® drug delivery platform may provide a medication option that significantly reduces dosing frequency. For people who rely on risperidone as part of their treatment regimen, oral weekly risperidone could vastly improve medication adherence and outcomes.”

This is a major step forward towards our goal of bringing long-acting oral medicines based on the LYNX drug delivery platform to the people who need them most and transforming how we take medicines. 

At Lyndra, we are passionate about building a healthier world through long-acting oral therapies. Today, we announced the close of a $101 Million Series E funding round to support that mission, led by Sarissa Capital Management LP and including SUN PHARMA and Polaris Partners These funds will support the development of therapies with our LYNX® drug delivery platform, including oral weekly risperidone (LYN-005), which is nearing completion of phase 3 clinical study.

“We appreciate the support our investors are providing as we complete our risperidone phase 3 trials and continue the development of our pipeline of oral weekly therapies through this round of financing,” said Jessica Ballinger, Lyndra President and CEO. “This investment validates the LYNX platform and moves us forward in our plans to bring our lead product candidate, oral weekly risperidone, through the regulatory pathway and to patients.”


We’re honored to share that our President & CEO, Jessica Ballinger , has been recognized in this year’s PharmaVoice Top 100. Congratulations, Jess! 

To learn more visit: https://lnkd.in/gwb4f7Rz
#leadership #pharmavoice100 #trailblazer 

August 31st marks International Overdose Awareness Day. As such, we honor those who have lost their lives to the drug overdose epidemic and acknowledge the grief of family and friends left behind. As a company working to create long-acting oral medications for people living with opioid use disorder with support from The National Institutes of Health’s The National Institute on Drug Abuse (NIDA), we want to take the time to remember the lives lost to the drug overdose epidemic. We look towards a future where people living with addiction have access to the help they need. #NIH #NIDA

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

Google Maps

WordPress

Co-Founder

Colin Gardner

President & Chief Operating Officer

Jessica Ballinger

Finance and Administration

Klas Holmlund

Chief Technology Officer

Orn Almarsson

Chief Executive Officer

Patricia Hurter

VP of Finance

Dana Vittum

Vice President, Manufacturing Science and Technology

David Geer

SVP, Commercial & Communications

Denise Strauss

Vice President, Data Compliance & Information Technology

Jackie Fernandes

SVP Alliance and Program Management, Oral Weekly Risperidone Program Leader

Jennifer McPhee McGovern

Giovanni Traverso

Catherine B. Reynolds

Amy Schulman

Zafrira Avnur

Executive Chairman & Co-Founder

Colin R. Gardner

CEO, President & Board Member

Ray Knox

Chief Engineering Officer

Chief Financial Officer

Raymond Knox

Chief Manufacturing Officer

New England Companies With More Than 10 Employees (Top 10K)

United States Companies With Less Than $1B in Revenue (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

East Coast Companies With Less Than $50M in Revenue (Top 10K)

Lyndra Therapeutics is a company that develops medicines for long-term drug release in an oral dose form. The company is developing oral ultra-long-acting and sustained-release therapies for central nervous system (CNS) disorders for broad applicability across multiple therapeutic areas, including approved drugs, allowing the medical community to ensure improved medication adherence and health outcomes while also helping to lower healthcare costs.

Series E - Lyndra Therapeutics

Series D - Lyndra Therapeutics

Series C - Lyndra Therapeutics

Bill & Melinda Gates Foundation

Grant - Lyndra Therapeutics

Series B - Lyndra Therapeutics

Series A - Lyndra Therapeutics

Venture Round - Lyndra Therapeutics

Watertown

Massachusetts

United States

North America

Lyndra extends shelf life of its Lynx oral drug delivery platform

Lyndra Therapeutics Raises $101 Million in Series E Funding

Sun Pharma to buy 16% stake of Lyndra Therapeutics for ₹249 crore

Sun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 million

Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears

Lyndra Therapeutics eyes $180M Series D for potential 2026 launch of once-weekly schizophrenia med

Oral weekly risperidone for schizophrenia and bipolar 1 disorder treatment, designed to improve medication adherence by reducing dosing frequency.

Oral weekly levomethadone for opioid use disorder maintenance treatment, aiming to simplify treatment and improve lives with less frequent dosing.

Oral weekly dapagliflozin for diabetes management, intended to enhance adherence and outcomes by minimizing daily pill burden.

Oral weekly rosuvastatin for dyslipidemia treatment, developed to increase medication adherence and reduce cardiovascular disease risk with fewer doses.

Oral monthly contraceptive aimed at providing pregnancy prevention with significantly reduced dosing frequency, enhancing access and satisfaction.

Oral biweekly ivermectin for malaria eradication, designed to reduce malaria transmission with less frequent dosing.

Puerto Rico

Canada

India

Asia

United Kingdom

Europe

HTML5

Modernizr

Google Analytics

Wordpress

GoDaddy

MailChannels Cloud

jQuery

Comodo PositiveSSL Certificates

Google Maps API

Google Fonts

Supernus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.

Supernus

Q Therapeutics is a biotechnology company specializing in developing cell-based therapies for central nervous system disorders.

Q Therapeutics

Psy Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of schizophrenia and other mental health disorders.

Psy Therapeutics

Ultivue is a life sciences company specializing in multiplex biomarker imaging solutions for research and clinical applications.

Ultivue

Ohana Biosciences is a biotechnology company focused on developing therapies for reproductive health and fertility.

Ohana Biosciences

Matterworks is a biotechnology company specializing in the development of novel drug delivery technologies and formulations.

Matterworks

Rani Therapeutics is a clinical-stage biotechnology company developing a robotic pill for the oral delivery of peptides, proteins, and therapeutic antibodies.

Rani Therapeutics

Lyndra Therapeutics is pioneering long-acting oral therapies through its proprietary LYNX™ drug delivery platform, with the potential to revolutionize oral drug delivery by providing week-long or longer dosing in an oral form. The company's core purpose is to reinvent medicine for a healthier world, and it has achieved rapid progress in formulating therapies and advancing products to the clinic.

news impact assignment basic	general	Mar 5, 2024 4:02 AM	deb15d2d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 4:02 AM	67ca8cd8
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	0d27f129
crunchbase profile	general	Nov 22, 2024 9:30 AM	fc3f278e
li profile	general	Mar 5, 2024 4:02 AM	59cf4ada
translate crunchbase fundingrounds	general	Nov 22, 2024 2:03 PM	efdada65
peers	general
news basic	general	Mar 5, 2024 4:02 AM	bf7fb994
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:LYNDRA

Lyndra Therapeutics